Dashboard
Manage Tickers

VTGN Vistagen Therapeutics, Inc.

Nasdaq vistagen.com


$ 4.05 $ -0.18 (-4.26 %)    

Thursday, 06-Nov-2025 11:33:24 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.93 $ -9.86 (-1.59 %)
DIA $ 468.51 $ -3.52 (-0.75 %)
SPY $ 670.29 $ -6.15 (-0.91 %)
TLT $ 89.79 $ 0.23 (0.26 %)
GLD $ 365.73 $ -1.45 (-0.39 %)
$ 4.18
$ 4.19
$ 4.01 x 100
$ 4.07 x 249
$ 4.02 - $ 4.19
$ 1.90 - $ 4.65
283,597
na
128.24M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 06-17-2025 03-31-2025 10-K
3 02-13-2025 12-31-2024 10-Q
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 06-11-2024 03-31-2024 10-K
7 02-13-2024 12-31-2023 10-Q
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 06-28-2023 03-31-2023 10-K
11 02-07-2023 12-31-2022 10-Q
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 06-23-2022 03-31-2022 10-K
15 02-10-2022 12-31-2021 10-Q
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 06-29-2021 03-31-2021 10-K
19 02-11-2021 12-31-2020 10-Q
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 06-30-2020 03-31-2020 10-K
23 02-13-2020 12-31-2019 10-Q
24 11-07-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 06-25-2019 03-31-2019 10-K
27 02-12-2019 12-31-2018 10-Q
28 10-29-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 06-26-2018 03-31-2018 10-K
31 02-12-2018 12-31-2017 10-Q
32 11-09-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 06-29-2017 03-31-2017 10-K
35 02-13-2017 12-31-2016 10-Q
36 11-14-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 06-24-2016 03-31-2016 10-K
39 02-16-2016 12-31-2015 10-Q
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vistagen-last-patient-in-palisade-3-phase-3-study-completes-trial-for-evaluation-of-fasedienol-to-treat-social-anxiety-disorder
Vistagen Last Patient In PALISADE-3 Phase ...
11/03/2025 13:42:44

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircui...

vistagen-therapeutics-cfo-cynthia-l-anderson-resigns-effective-october-15-2025
Vistagen Therapeutics' CFO Cynthia L. Ande...
09/15/2025 20:56:22

-SEC Filing

vistagen-therapeutics-q1-eps-047-beats-050-estimate-sales-24400k-miss-65000k-estimate
VistaGen Therapeutics Q1 EPS $(0.47) Beats...
08/07/2025 20:51:27

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

insights-ahead-vistagen-therapeuticss-quarterly-earnings
Insights Ahead: VistaGen Therapeutics's Qu...
08/06/2025 21:02:11

vistagen-therapeutics-files-for-offering-of-up-to-175m-of-common-stock
Vistagen Therapeutics Files For Offering O...
06/17/2025 20:53:32

-SEC Filing

vistagen-therapeutics-q4-eps-044-beats-050-estimate-sales-1500k
VistaGen Therapeutics Q4 EPS $(0.44) Beats...
06/17/2025 20:41:43

Core News & Articles
Earnings Scheduled For June 17, 2025
06/17/2025 08:32:11

insights-into-vistagen-therapeuticss-upcoming-earnings
Insights into VistaGen Therapeutics's Upco...
06/16/2025 14:02:10

vistagen-therapeutics-provides-update-for-us-registration-directed-palisade-3-phase-3-trial-evaluating-fasedienol-for-acute-treatment-of-social-anxiety-disorder
Vistagen Therapeutics Provides Update For ...
06/02/2025 12:34:24

Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026

vistagen-therapeutics-q3-eps-046-beats-051-estimate-sales-23400k-beat-18000k-estimate
VistaGen Therapeutics Q3 EPS $(0.46) Beats...
02/13/2025 21:42:19

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of...

earnings-scheduled-for-february-13-2025
Earnings Scheduled For February 13, 2025
02/13/2025 08:32:25

vistagen-granted-us-patent-for-av-101-to-treat-neuropathic-pain
Vistagen Granted US Patent For AV-101 To T...
02/05/2025 13:35:27

vistagen-announces-uspto-patent-grant-for-av-101-oral-non-opioid-neuropathic-pain-treatment-expiring-2034
Vistagen Announces USPTO Patent Grant For ...
02/05/2025 13:35:02

vistagen-announces-results-from-exploratory-phase-2a-study-of-ph284-in-cancer-cachexia-ph284-nasal-spray-demonstrated-improvements-to-subjective-feelings-of-hunger-in-cancer-patients
Vistagen Announces Results From Explorator...
01/14/2025 13:32:19

PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patientsPH284 is the fifth pherine produ...

vistagen-announces-phase-3-program-for-social-anxiety-disorder-with-fasedienol-first-enrollment-in-us-study-for-efficacy-safety-tolerability-during-public-speaking-challenge
Vistagen Announces Phase 3 Program For Soc...
01/10/2025 13:37:27

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety...

vistagen-therapeutics-q2-2025-gaap-eps-042-misses-039-estimate-sales-183000k-miss-223333k-estimate
VistaGen Therapeutics Q2 2025 GAAP EPS $(0...
11/08/2024 00:08:04

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate ...

vistagen-initiates-palisade-4-phase-3-study-of-fasedienol-for-acute-treatment-of-social-anxiety-disorder
Vistagen Initiates PALISADE-4 Phase 3 Stud...
09/23/2024 12:32:12

vistagen-therapeutics-q1-2025-adj-eps-035-beats-041-estimate-sales-8400k-miss-30000k-estimate
VistaGen Therapeutics Q1 2025 Adj EPS $(0....
08/13/2024 20:23:27

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of...

vistagen-expands-global-intellectual-property-portfolio-with-new-patents-for-ph80-nasal-spray-investigational-treatment-for-migraine-hot-flashes-due-to-menopause-premenstrual-dysphoric-disorder-and-dysmenorrhea
Vistagen Expands Global Intellectual Prope...
07/09/2024 12:34:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION